Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 11/20 | 0.53 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639291 | 0.88 | ROCK2 (0.75) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27249094 | 0.85 | SLC2A1 (0.52) | ROCK2ROCK1SLC2A1SLC2A3 | |
| Trifluoroacetic Acid SCHEMBL29576130 | 0.85 | ROCK2 (0.68) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248885 | 0.84 | SLC2A1 (0.57) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27249055 | 0.84 | ROCK2 (0.55) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248869 | 0.84 | SLC2A1 (0.55) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248812 | 0.83 | SLC2A1 (0.57) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248888 | 0.82 | SLC2A1 (0.56) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248806 | 0.82 | SLC2A1 (0.59) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL27248475 | 0.81 | SLC2A1 (0.58) | ROCK2ROCK1SLC2A1SLC2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | ROCK2 3701/4885ROCK1 3618/4885SLC2A1 1/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | ROCK2 3701/4885ROCK1 3618/4885SLC2A1 1/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | ROCK2 3707/4885ROCK1 3577/4885SLC2A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.